# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-013560
Filing Date
2022-08-15
Accepted
2022-08-15 07:09:46
Documents
45
Period of Report
2022-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | plx-20220630x10q.htm iXBRL | 10-Q | 966608
2 | EX-3.5 | plx-20220630xex3d5.htm | EX-3.5 | 9573
3 | EX-31.1 | plx-20220630xex31d1.htm | EX-31.1 | 10030
4 | EX-31.2 | plx-20220630xex31d2.htm | EX-31.2 | 10390
5 | EX-32.1 | plx-20220630xex32d1.htm | EX-32.1 | 6123
6 | EX-32.2 | plx-20220630xex32d2.htm | EX-32.2 | 6149
7 | GRAPHIC | plx-20220630x10q005.jpg | GRAPHIC | 113571
8 | GRAPHIC | plx-20220630x10q006.jpg | GRAPHIC | 100730
9 | GRAPHIC | plx-20220630x10q007.jpg | GRAPHIC | 35810
| Complete submission text file | 0001558370-22-013560.txt |  | 4127230

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
10 | EX-101.SCH | plx-20220630.xsd | EX-101.SCH | 27312
11 | EX-101.CAL | plx-20220630_cal.xml | EX-101.CAL | 34234
12 | EX-101.DEF | plx-20220630_def.xml | EX-101.DEF | 127031
13 | EX-101.LAB | plx-20220630_lab.xml | EX-101.LAB | 207593
14 | EX-101.PRE | plx-20220630_pre.xml | EX-101.PRE | 192712
39 | EXTRACTED XBRL INSTANCE DOCUMENT | plx-20220630x10q_htm.xml | XML | 402552

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 221162288
SIC: 2836 Biological Products, (No Diagnostic Substances)